Trader: Time To Get...
Health Care: Drugs
Human Genome Sciences Inc (HGSI: NASDAQ)
$13.59 -0.29 | -2.09%
05/24/12 - 11:35 AM ET
2.58M / 7.96M
Vol / Avg. Vol:13.78 / 13.88
Open / Prev. Close:13.51 - 13.83
Today's Range:6.51 - 27.46
52 Wk Range:87.82%
Performance YTD:TheStreet Rating:
Portfolios with HGSI
- Portfolio NameUser Type
- Contributor6 Drug Stocks Unworthy of B...
- ContributorUnder-$10 Setting Up To Tra...
- Userdividend stocks and penny s...
- UserNick
- ContributorEarnings Short Squeeze Play...
- UserTop Ten Stock Picks by Core...
- UserLong Term Stock Picks by Co...
- ContributorEarnings Short Squeeze Play...
- Contributor5 Biotech Drug-Launch Stock...
- Userpossible investments
Latest HGSI Headlines from TheStreet
- Analysts' Actions: ARO, DUK, PPG 05.24.12 | 08:05 am
- Bankia Customers Withdraw 1 Billion Euro: Hot Trends
05.17.12 | 12:05 pm - Bankia Customers Withdraw 1B Euros in One Week: Hot Trends 05.17.12 | 09:05 am
- Hot Biotech Stocks Traded by Hedge Funds in First Quarter 05.16.12 | 07:05 am
- A Health Care Fortnight for the Record Books 05.14.12 | 07:05 am
- Human Genome Sciences Inc (HGSI): Today's Featured Drugs Loser 05.10.12 | 05:05 pm
- Business Highlights 05.09.12 | 06:05 pm
- GlaxoSmithKline Takes Human Genome Bid Hostile: Hot Trends 05.09.12 | 10:05 am
- Glaxo's Bid for Human Genome Turns Hostile: Hot Trends 05.09.12 | 08:05 am
- 5 Things You Should Know Before the Stock Market Opens 05.09.12 | 06:05 am
Press Releases for HGSI
- Human Genome Sciences Board Of Directors Unanimously Determines GlaxoSmithKline Unsolicited Tender Offer Is Inadequate And Not In The Best Interests Of Stockholders - Business Wire 05.17.12 | 07:05 am
- Human Genome Sciences Announces First Quarter 2012 Financial Results - Business Wire 04.24.12 | 04:04 pm
- Human Genome Sciences To Sponsor Conference Call To Discuss First Quarter 2012 Financial Results - Business Wire 04.20.12 | 12:04 pm
- Human Genome Sciences Announces Unsolicited Offer From GlaxoSmithKline; HGS Board Of Directors Authorizes Exploration Of Strategic Alternatives - Business Wire 04.19.12 | 05:04 am
- FYI From Human Genome Sciences: GlaxoSmithKline Announces Further Data From Phase 3 Trials Of Albiglutide - Business Wire 04.03.12 | 07:04 am
- Human Genome Sciences Invites Investors To Listen To Webcast Of Presentation At Barclays Capital Conference - Business Wire 03.09.12 | 08:03 am
- Human Genome Sciences Invites Investors To Listen To Webcast Of Presentation At Cowen And Company Conference - Business Wire 03.01.12 | 08:03 am
- Human Genome Sciences Announces Fourth-Quarter And Full-Year Financial Results And Key Developments - Business Wire 02.27.12 | 04:02 pm
- Human Genome Sciences To Sponsor Conference Call To Discuss Fourth-Quarter And Full-Year 2011 Financial Results - Business Wire 02.22.12 | 04:02 pm
- Human Genome Sciences Invites Investors To Listen To Webcast Of Presentation At Leerink Swann Conference - Business Wire 02.13.12 | 04:02 pm
Partner Headlines for HGSI
- Healthcare Biz Recap: GSK Shakes on Human Genome, Express Scripts Desires a Date Walgreen - Wall St. Cheat Sheet 05.23.12 | 11:05 am
- Glaxo Fails to Impress HGSI - Analyst Blog - Zacks 05.18.12 | 05:05 pm
- 4 New Reasons To Be Bullish On Sanofi Now - Seeking Alpha 05.13.12 | 09:05 am
- Company News for May 10, 2012 - Corporate Summary - Zacks 05.10.12 | 10:05 am
- Ahead of Wall Street - May 9, 2012 - Ahead of Wall Street - Zacks 05.09.12 | 09:05 am
- Biotech ETFs In Focus: XBI Vs. IBB - Seeking Alpha 04.25.12 | 09:04 am
- The Appeal Of Human Genome Sciences While It's Still Under $10 - Seeking Alpha 04.04.12 | 08:04 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- Cytori Is A Compelling Short Sale Opportunity - Seeking Alpha 03.19.12 | 09:03 am
- Human Genome Sciences Trades Up 4% on Q4 Results - Benzinga 02.27.12 | 04:02 pm
